The Chemours Company (NYSE:CC) Shares Purchased by Advisors Asset Management Inc.

Advisors Asset Management Inc. boosted its position in The Chemours Company (NYSE:CC) by 146.6% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 235,238 shares of the specialty chemicals company’s stock after acquiring an additional 139,836 shares during the quarter. Advisors Asset Management Inc. owned 0.16% of Chemours worth $3,976,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC lifted its stake in shares of Chemours by 99.7% during the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company’s stock worth $26,000 after purchasing an additional 765 shares in the last quarter. Truvestments Capital LLC acquired a new position in shares of Chemours during the third quarter worth about $35,000. Brooklyn Investment Group acquired a new position in shares of Chemours during the third quarter worth about $37,000. Prospera Private Wealth LLC acquired a new position in shares of Chemours during the third quarter worth about $75,000. Finally, KBC Group NV lifted its stake in shares of Chemours by 19.5% during the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company’s stock worth $91,000 after purchasing an additional 728 shares in the last quarter. Institutional investors and hedge funds own 76.26% of the company’s stock.

Chemours Stock Down 0.6 %

Shares of Chemours stock opened at $14.67 on Friday. The company has a quick ratio of 0.92, a current ratio of 1.68 and a debt-to-equity ratio of 6.70. The firm has a market cap of $2.19 billion, a P/E ratio of 25.73 and a beta of 2.00. The Chemours Company has a fifty-two week low of $13.09 and a fifty-two week high of $29.21. The business has a 50-day moving average price of $16.96 and a 200 day moving average price of $18.36.

Chemours (NYSE:CC) last issued its earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.01. Chemours had a return on equity of 26.54% and a net margin of 1.51%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. On average, sell-side analysts forecast that The Chemours Company will post 2.03 earnings per share for the current fiscal year.

Chemours Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, March 14th. Shareholders of record on Friday, February 28th were paid a $0.25 dividend. The ex-dividend date of this dividend was Friday, February 28th. This represents a $1.00 dividend on an annualized basis and a yield of 6.82%. Chemours’s payout ratio is currently 175.44%.

Analyst Ratings Changes

A number of analysts have recently issued reports on CC shares. Truist Financial started coverage on Chemours in a research report on Tuesday, January 28th. They set a “buy” rating and a $27.00 target price on the stock. Barclays dropped their target price on Chemours from $23.00 to $19.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. Morgan Stanley dropped their target price on Chemours from $25.00 to $22.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. The Goldman Sachs Group dropped their target price on Chemours from $24.00 to $21.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $25.00 target price on shares of Chemours in a research report on Thursday, December 12th. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.11.

About Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.